ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission"

  • Abstract Number: 0522 • ACR Convergence 2021

    Genetics of Rheumatoid Arthritis Remission; HLA-SE Associated with Remission in Anti-CCP Positive Patients

    Marc Maurits1, Samantha Jurado Zapata1, Yann Abraham2, Erik van den Akker1, Anne Barton3, Philip Brown4, Andrew P Cope5, Isidoro Gonzalez-Alvaro6, Carl Goodyear7, Annette H.M van der Helm-van Mil1, Xinli Hu8, Tom WJ Huizinga1, Martina Johannesson9, Lars Klareskog10, Dennis Lendrem11, Iain McInnes12, Fraser Morton7, Caron Paterson7, Duncan Porter13, Arthur Pratt11, Luis Rodriguez Rodriguez14, Daniela Sieghart15, Paul Studenic16, Suzanne Verstappen17, Leonid Padyukov9, Aaron Winkler18, John Isaacs19 and Rachel Knevel1, 1Leiden University Medical Center, Leiden, Netherlands, 2Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium, 3University of Manchester, Manchester, United Kingdom, 4Newcastle University, Newcastle, United Kingdom, 5King's College London, London, United Kingdom, 6Rheumatology Service. La Princesa University Hospital, Madrid, Spain, 7University of Glasgow, Glasgow, United Kingdom, 8Pfizer, Saint Peters, MO, 9Karolinska Institutet, Stockholm, Sweden, 10Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 11Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 12University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 13University of Glasgow, Bearsden, United Kingdom, 14Hospital Clinico San Carlos, Madrid, Spain, 15Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 16Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 17School of Social Sciences, The University of Manchester, Manchester, United Kingdom, 18Pfizer, Cambridge, MA, 19Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) patients capable of reaching clinical remission potentially have a specific genetic profile that allows them to regain immune tolerance. The identification…
  • Abstract Number: 0844 • ACR Convergence 2021

    Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort

    Stephanie Keeling1, Britney Jones2, Jill Hall3, Joanne Homik4, Anthony Russell1, Luck Lukusa5, Sasha Bernatsky6 and Walter Maksymowych7, 1Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 2University of Alberta/University of Calgary, Edmonton, AB, Canada, 3Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 6McGill University, Montréal, QC, Canada, 7Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada

    Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…
  • Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium

    Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis

    Angela Chun1, Lutfiyya Muhammad 2 and Deirdre De Ranieri 3, 1Lurie Children's Hospital, Chicago, Iowa, 2Northwestern University Feinberg School of Medicine, Chicago, 3Lurie Children's Hospital, Chicago, Illinois

    Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
  • Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium

    Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile

    Sara Concha1, Pamela Morales 2, Eduardo Talesnik 1 and Arturo Borzutzky 1, 1Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, 2Department of Pediatric, Clinica Las Condes, Santiago, Chile

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
  • Abstract Number: L08 • 2019 ACR/ARP Annual Meeting

    Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial

    Siri Lillegraven1, Nina Sundlisater 2, Anna-Birgitte Aga 3, Joe Sexton 1, Inge Christoffer Olsen 4, Hallvard Fremstad 5, Cristina Spada 6, Tor Magne Madland 7, Christian Høili 8, Gunnstein Bakland 9, Åse Lexberg 10, Inger Johanne Widding Hansen 11, Inger Myrnes Hansen 12, Hilde Haukeland 13, Maud-Kristine Aga Ljoså 14, Ellen Moholt 15, Till Uhlig 16, Daniel Solomon 17, Désirée van der Heijde 18, Tore Kvien 16 and Espen A Haavardsholm 15, 1Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 4Oslo University Hospital, Oslo, Norway, 5Ålesund Hospital, Helse Møre og Romsdal, Ålesund, Norway, 6Lillehammer Hosptial for Rheumatic Diseases, Lillehammer, Norway, 7Haukeland University Hospital, Bergen, Norway, 8Hospital Østfold HF, Moss, Norway, 9University Hospital of North Norway, Tromsø, Norway, 10Drammen Hospital, Vestre Viken HF, Drammen, Norway, 11Sørlandet Hospital HF, Kristiansand, Norway, 12Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, 13Martina Hansens Hospital, Bærum, Norway, 14Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, 15Diakonhjemmet Hospital, Oslo, Norway, 16Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 17Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 18Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…
  • Abstract Number: L11 • 2019 ACR/ARP Annual Meeting

    Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Thomas W.J. Huizinga 4, Gustavo Citera 5, Clifton Bingham 6, Subhashis Banerjee 7, Benjamin Soule 8, Marleen Nys 9, Sean Connolly 10, Robert Wong 10, Kuan-Hsiang Gary Huang 7 and Roy Fleischmann 11, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 6Johns Hopkins University, Baltimore, 7Bristol-Myers Squibb, Princeton, NJ, 8Bristol-Myers Squibb, Princeton, New Jersey, 9Bristol-Myers Squibb, Braine L'Alleud, Belgium, 10Bristol-Myers Squibb, Princeton, 11Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
  • Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting

    Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis

    Ekaterina Alexeeva1, Rina Denisova 2, Tatyana Dvoryakovskaya 2, Ksenia Isaeva 2, Ivan Kriulin 2, Alina Alshevskaya 3 and Andrey Moskalev 3, 1National Medical Research Center of Children`s Health, Moscow, Russia, 2NMRCCH, Moscow, Russia, 3Biostatistics and Clinical Trials Center, Novosibirsk, Russia

    Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…
  • Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting

    Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations

    Nina Sundlisater1, Anna-Birgitte Aga 2, Ulf Sundin 3, Hilde Hammer 1, Till Uhlig 4, Tore Kvien 4, Espen Haavardsholm 4 and Siri Lillegraven 5, 1Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway

    Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…
  • Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting

    Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study

    Hanna Källmark1, Jon Einarsson 2, Jan-Åke Nilsson 3 and Meliha Kapetanovic 2, 1Lund University, Lund, Sweden, 2Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, 3Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden

    Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…
  • Abstract Number: 837 • 2019 ACR/ARP Annual Meeting

    Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Lykke Midtbøll Ørnbjerg 2, Anne Gitte Loft 3, Tore Kvien 4, Adrian Ciurea 5, Herman Mann 6, Kari K. Eklund 7, Ayten Yazici 8, Maria José Santos 9, Johan Askling 10, Ziga Rotar 11, Bjorn Gudbjornsson 12, Manuel Pombo-Suarez 13, Catalin Codreanu 14, Irene van der Horst-Bruinsma 15, Eirik Kristianslund 16, Michael J. Nissen 17, Karel Pavelka 6, Nina Trokovic 18, Nevsun Inanc 19, Elsa Vieira-Sousa 20, Daniela DiGuiseppe 21, Matija Tomsic 22, Arni Jon Geirsson 23, Ruxandra IONESCU 24, Marleen van de Sande 25, Florenzo Iannone 26, Carlos Sánchez-Piedra 27, Gareth Jones 28, Lise Hyldstrup 2, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5University Hospital Zürich, Zürich, Switzerland, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 7ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 8Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Karolinska Institutet, Stockholm, Sweden, 11UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 14Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 15Amsterdam University Medical Center, Amsterdam, Netherlands, 16Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 17University Hospital Geneva, Geneva, Switzerland, 18Helsinki University Central Hospital, Helsinki, Finland, 19Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, 20Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 21Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 22Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 23Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 24SPITALUL CLINIC SFANTA MARIA, Bucharest, 25Amsterdam UMC, Amsterdam, Netherlands, 26Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 27Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 28University of Aberdeen, Aberdeen, United Kingdom, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates…
  • Abstract Number: 1172 • 2019 ACR/ARP Annual Meeting

    The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging

    Scott Brunet 1, Peter Salat 2, Glen Hazlewood 3, Klaus Engelke 4, Cheryl Barnabe 3 and Sarah Manske3, 1University of Calgary, Calgary, Canada, 2University of Calgary, Calary, Canada, 3University of Calgary, Calgary, AB, Canada, 4Erlangen University Hospital, Department of Medicine, Erlangen, Germany

    Background/Purpose: Many RA patients in clinical remission have evidence of bone marrow edema (BME) on magnetic resonance imaging (MRI), with radiographic bone damage progression appearing…
  • Abstract Number: 1242 • 2019 ACR/ARP Annual Meeting

    Impact of Smoking Status on Remission in Hidradenitis Suppurativa

    Amil Agarwal 1, Marissa Mangini 1, Derek Jones 1, Catherine Hood 1, Richard Amdur 1 and Victoria Shanmugam2, 1The George Washington University School of Medicine and Health Sciences, Washington, DC, 2George Washington University, Georgetown, DC

    Background/Purpose: Hidradenitis Suppurativa (HS) is an inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The molecular drivers of HS are poorly…
  • Abstract Number: 1282 • 2019 ACR/ARP Annual Meeting

    Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis

    Prasanth Lingamaneni1, Carrie Richardson 2, Soumyasri Kambhatla 3 and Augustine Manadan 2, 1John H. Stroger Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL, 3John H. Stroger Hospital of Cook County, Chicago

    Background/Purpose: Adults with polymyositis demonstrate wide variability in responses to treatment, and the risk factors for failure to achieve remission in polymyositis are largely unknown. …
  • Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting

    Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

    Maria Powell1, Vivian Bykerk 2, Orit Schieir 3, Marie-France Valois 4, Susan J. Bartlett 5, Louis Bessette 6, Gilles Boire 7, Carol Hitchon 8, Edward Keystone 9, Janet Pope 10, Carter Thorne 11, Diane Tin 12 and Glen Hazlewood 1, 1University of Calgary, Calgary, AB, Canada, 2Hospital for Special Surgery, New York City, NY, 3University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, 4McGill University, Montreal, Canada, 5McGill University, Montreal, QC, Canada, 6Laval University, Quebec City, QC, Canada, 7Sherbrooke University, Sherbrooke, QC, Canada, 8University of Manitoba, Winnipeg, Canada, 9Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 10Western University, London, ON, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Southlake Regional Health Centre, Newmarket, Canada

    Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
  • Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting

    Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis

    MASAOMI YAMASAKI1, 1Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology